

KINETICS PORTFOLIOS TRUST - MASTER INVESTMENT PORTFOLIOS

The Medical Portfolio

Portfolio of Investments - March 31, 2020 (Unaudited)

COMMON STOCKS - 99.15%	Shares	Value
Chemical Manufacturing - 1.49%		
Editas Medicine, Inc.*	6,000	\$ 118,980
Intellia Therapeutics, Inc.*	8,000	97,840
		<u>216,820</u>
Pharmaceutical and Medicine Manufacturing - 96.21%		
AbbVie, Inc. ^c	10,000	761,900
Agenus, Inc.*	148	363
Alkermes plc*	21,000	302,820
AMGEN, Inc. ^c	4,000	810,920
Arena Pharmaceuticals, Inc.*	4,500	189,000
AstraZeneca plc - ADR ^c	20,000	893,200
Biogen, Inc.* ^c	3,750	1,186,425
Bristol-Myers Squibb Company ^c	23,500	1,309,890
Celldex Therapeutics, Inc.*	1,752	2,908
Eli Lilly & Company ^c	8,500	1,179,120
Gilead Sciences, Inc. ^c	11,000	822,360
GlaxoSmithKline plc - ADR ^c	21,673	821,190
Immune Pharmaceuticals, Inc.*	1	-
Ionis Pharmaceuticals, Inc.*	12,000	567,360
Johnson & Johnson ^c	8,000	1,049,040
Merck & Co., Inc. ^c	15,000	1,154,100
Merrimack Pharmaceuticals, Inc.	7,500	16,125
Novartis AG - ADR ^c	14,000	1,154,300
Pacific Biosciences of California, Inc.*	12,000	36,720
Pfizer, Inc. ^c	30,000	979,200
Sanofi - ADR* ^c	17,000	743,240
Xenon Pharmaceuticals, Inc.*	7,000	79,380
		<u>14,059,561</u>
Research and Development in Biotechnology (except Nanobiotechnology) - 1.45%		
CRISPR Therapeutics AG*	5,000	212,050
TOTAL COMMON STOCKS		
(cost \$9,940,468)		<u>14,488,431</u>
RIGHTS - 0.25%		
Pharmaceutical and Medicine Manufacturing - 0.18%		
Bristol-Myers Squibb Company*	7,000	26,600
Scientific Research and Development Services - 0.07%		
Ligand Pharmaceuticals, Inc.* ^f	44,000	8,800
Ligand Pharmaceuticals, Inc.* ^f	44,000	1,056
Ligand Pharmaceuticals, Inc.*	44,000	127
Ligand Pharmaceuticals, Inc.* [#]	44,000	396
		<u>10,379</u>
TOTAL RIGHTS		

(cost \$14,910)

36,979

TOTAL INVESTMENTS - 99.40%

(cost \$9,955,378)

\$ 14,525,410

Percentages are stated as a percent of net assets.

* - Non-income producing security.

^ - This security or a portion of this security was out on loan at March 31, 2020. Total loaned securities had a market value of \$812,968 at March 31, 2020. The remaining contractual maturities of all of the securities lending transactions were overnight and continuous. The total collateral for the loaned securities was cash in the amount of \$826,056.

- Contingent value right (contingent upon profitability of company).

° - Significant Investment - Greater than 5% of net assets.

f - Level 2 Investment.

ADR - American Depositary Receipt.

Security Valuation

Master Portfolios and Spin-off Fund equity securities that are listed on a securities exchange for which market quotations are readily available are valued at the last quoted sale price on the day the valuation is made. Price information on listed securities is taken from the exchange where the security is primarily traded. All equity securities, including exchange-traded funds, that are traded using the National Association of Securities Dealers' Automated Quotation System ("NASDAQ") are valued using the NASDAQ Official Closing Price ("NOCP"). In the event market quotations are not readily available or if events occur that may materially affect the value of a particular security between the time trading ends on a particular security and the close of regular trading on the New York Stock Exchange ("NYSE"), "fair value" will be determined. Unlisted equity securities and listed equity securities not traded on the valuation date for which market quotations are readily available are valued at the last bid price. Futures, options on futures and swap contracts that are listed or traded on a national securities exchange, commodities exchange, contract market or over-the-counter markets and are freely transferrable will be valued at the composite price, using the National Best Bid and Offer quotes ("NBBO"). NBBO consists of the highest bid price and lowest ask price across any of the exchanges on which an option is quoted, thus providing a view across the entire U.S. options marketplace. Composite option pricing calculates the mean of the highest bid price and lowest ask price across the exchanges where the option is traded. If a composite option price is not available, then a quote provided by one of the authorized pricing vendors will be used. If neither a composite price nor a quote from an authorized pricing provider is available, and it is the day of expiration or post-expiration, expiring options will be priced at intrinsic value. Non-exchange-traded options for which over-the-counter quotations are not readily available are valued at the mean between the last bid and asked quotations. Debt obligations (including convertible securities) that are either investment grade or below investment grade and irrespective of days to maturity are valued at evaluated mean by one of the authorized third party pricing agents which rely on various valuation methodologies such as matrix pricing and other analytical pricing models as well as market transactions and dealer quotations. Certain instruments, such as repurchase agreements and demand notes, do not have values from third parties and are valued at amortized cost. Investments in registered open-end investment companies (including money market funds), other than exchange-traded funds, are valued at their reported net asset value ("NAV").

Other assets and securities for which no quotations are readily available (including restricted securities) will be valued in good faith at fair value using methods determined by the Board of Trustees of the Master Portfolios and Spin-off Fund. In determining the fair value of a security, the Board of Trustees shall take into account the relevant factors and surrounding circumstances, which may include: (i) the nature and pricing history (if any) of the security; (ii) whether any dealer quotations for the security are available; (iii) possible valuation methodologies that could be used to determine the fair value of the security; (iv) the recommendation of the portfolio manager of the Portfolios with respect to the valuation of the security; (v) whether the same or similar securities are held by other funds managed by the Adviser or other funds and the method used to price the security in those funds; (vi) the extent to which the fair value to be determined for the security will result from the use of data or formula produced by third parties independent of the Adviser; (vii) the liquidity or illiquidity of the market for the security; and (viii) the value of a foreign security traded on other foreign markets. At March 31, 2020, 0.00% and 0.00% of the net assets of The Internet Portfolio and The Paradigm Portfolio, respectively, were fair valued securities. The Master Portfolios and Spin-off Fund did not hold any fair valued securities at March 31, 2020.

Summary of Fair Value Exposure

Various inputs are used in determining the value of the Master Portfolio's and Spin-off Fund's investments. These inputs are summarized in the three broad levels listed below:

- Level 1 - Unadjusted quoted prices in active markets for identical assets or liabilities that a Master Portfolio or the Spin-off Fund has the ability to access.
- Level 2 - Observable inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly or indirectly. These inputs may include quoted prices for the identical instrument on an inactive market, prices for similar instruments, interest rates, prepayment speeds, credit risk, yield curves, default rates and similar data.
- Level 3 - Unobservable inputs for the asset or liability, to the extent relevant observable inputs are not available, representing a Master Portfolio or the Spin-off Fund's own assumptions about the assumptions a market participant would use in valuing the asset or liability, and would be based on the best information available.

The availability of observable inputs can vary from security to security and is affected by a wide variety of factors, including, for example, the type of security, whether the security is new and not yet established in the marketplace, the liquidity of markets, and other characteristics particular to the security. To the extent that valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised in determining fair value is greatest for instruments categorized in Level 3.

The inputs used to measure fair value may fall into different levels of the fair value hierarchy. In such cases, for disclosure purposes, the level in the fair value hierarchy within which the fair value measurement falls in its entirety, is determined based on the lowest level

input that is significant to the fair value measurement in its entirety.

The Medical Portfolio

The following is a summary of the inputs used to value The Medical Portfolio's net assets as of March 31, 2020:

<u>Assets[^]</u>	<u>Level 1</u>	<u>Level 2</u>	<u>Level 3</u>	<u>Total</u>
Common Stocks	\$ 14,488,431	\$ –	\$ –	\$ 14,488,431
Rights	27,123	9,856	–	36,979
Total Investments in Securities	<u>\$ 14,515,554</u>	<u>\$ 9,856</u>	<u>\$ –</u>	<u>\$ 14,525,410</u>

As of March 31, 2020, there were no investments in Level 3 securities.

During the three-month period ended March 31, 2020, there were no transfers into or out of Level 3.

[^] See Portfolio of Investments for breakout of investments by industry classification.